• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Synaptogenix Appoints Crypto Expert to Lead Digital Asset Treasury Strategy Focused Exclusively on Top-Valued AI Token

    6/9/25 9:00:00 AM ET
    $SNPX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $SNPX alert in real time by email

    Singular focus on Bittensor (TAO), the leading AI token by

    adoption and market capitalization

    James Altucher to lead TAO token strategy initiatives

    Planned initial acquisition of $10 million in TAO equates to over two times the Company's 

    current market capitalization; total acquisition target of $100 million

    NEW YORK, June 9, 2025 /PRNewswire/ -- Synaptogenix, Inc. (NASDAQ:SNPX) ("Synaptogenix" or the "Company") today announced its launch of a differentiated cryptocurrency treasury strategy focused exclusively on the artificial intelligence (AI) crypto token "TAO," which is currently the top AI token by market capitalization and adoption. Well-known cryptocurrency and AI expert James Altucher will lead a TAO-based revenue generation strategy targeting staking yield and token appreciation.

    Synaptogenix plans to acquire $10 million in TAO tokens initially, which amounts to over two times the Company's current market valuation. The Company's strategy is targeted to acquire $100 million of TAO tokens. The initial acquisition will be funded by the Company's significant cash reserves and well-capitalized balance sheet.

    Joshua Silverman, Chairman of the Board, stated, "Near the end of 2024, our Board of Directors began exploring value creation opportunities to best utilize our significant cash reserves. We have witnessed an increasing number of public and private companies allocate digital assets to their corporate treasuries successfully or use them as part of their business strategies. We believe the leading AI token, TAO, offers the best outlook for growth and adoption as well as the best opportunity to create and preserve value for our stockholders. We are fortunate to bring on James Altucher, a world-class authority on both AI and crypto, to drive revenue generation and TAO staking strategies in pursuit of significantly increasing shareholder value."

    "Based on our initial review, we believe the fixed market supply of 21 million TAO tokens alongside rapidly increasing global demand for AI development and adaptation makes TAO a compelling cryptocurrency," Silverman concluded.

    Mr. Altucher is an accomplished entrepreneur, venture capitalist, writer and author with decades of expertise in emerging technologies including crypto and AI. As an early proponent of Bitcoin, he created the first "Bitcoin-only" store. He has also published numerous academic papers on AI and delivered keynotes at prestigious AI conferences.

    "The AI industry is expected to grow tenfold between now and 2030, and some percentage of every dollar allocated to AI is expected to go towards decentralized AI where TAO is the clear leader. I am excited to be a part of what I believe is the only pure play public company focused on the convergence between crypto and AI as both industries continue to grow exponentially," said Altucher.

    TAO is the native token created for Bittensor, a decentralized blockchain network for machine learning and AI. Bittensor's open access and ownership environment for creating, training, and evaluating AI models is designed to democratize AI development. The network incentivizes participants, including miners and validators, based on the value of their contributions, as measured by information theory—such as the novelty, relevance, or efficiency of shared AI knowledge. Rewards are distributed in the form of TAO tokens.

    Synaptogenix intends to change its name and ticker symbol in accordance with its digital asset treasury strategy based on the AI token TAO. A new corporate website is also under development. More information will be available within the next several months.

    Synaptogenix announced that it has entered into securities purchase agreements for a $5.5 million financing, including James Altucher, involving the sale of 5,500 shares of its newly issued Series D convertible preferred stock ("preferred stock"), with a stated value of $1,000 per share, convertible into shares of its common stock in a private placement and five year common stock purchase warrants, which is expected to close on or about June 10, 2025 subject to the satisfaction of customary closing conditions.

    The shares of Series D preferred stock have a conversion price of $3.00 per share. The warrants have an exercise price of $3.00 per common share. 

    The financing, consulting agreement with Mr. Altucher and certain management changes are more fully disclosed in the current report on Form 8-K filed with the SEC this morning.

    Forward-Looking Statements

    Any statements contained in this press release by Synaptogenix that do not describe historical facts may constitute forward-looking statements. Such forward-looking statements are subject to risks and uncertainties and other influences, many of which the Company has no control over. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. These and other factors are identified and described in more detail in the Company's filings with the Securities and Exchange Commission. The Company does not undertake to update these forward-looking statements.

    Contact

    800-811-5591

    [email protected]

    Cision View original content:https://www.prnewswire.com/news-releases/synaptogenix-appoints-crypto-expert-to-lead-digital-asset-treasury-strategy-focused-exclusively-on-top-valued-ai-token-302476176.html

    SOURCE Synaptogenix, Inc.

    Get the next $SNPX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $SNPX

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $SNPX
    Financials

    Live finance-specific insights

    See more
    • Synaptogenix Announces Changes to Scientific Advisory Board in Preparation for Phase 2 Data

      Conference Call to be held Tuesday, July 26th at 4:30pm ET NEW YORK, July 26, 2022 /PRNewswire/ -- Synaptogenix, Inc. (NASDAQ:SNPX) ("the Company"), a clinical-stage biopharmaceutical company developing regenerative therapeutics for neurodegenerative disorders, today announced changes to its Scientific Advisory Board (SAB) in preparation for Phase 2 data from its Phase 2b clinical trial of Bryostatin-1 for patients suffering from advanced and moderately severe Alzheimer's disease (AD).  The SAB is comprised of industry and academic leaders in science and drug development and will be instrumental in the further development of the Company's regenerative therapies across AD, Fragile X syndrome,

      7/26/22 9:15:00 AM ET
      $SNPX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Synaptogenix Announces Corporate Update Conference Call

      NEW YORK, July 21, 2022 /PRNewswire/ -- Synaptogenix, Inc. (NASDAQ:SNPX) ("the Company"), a clinical-stage biopharmaceutical company developing regenerative therapeutics for neurodegenerative disorders, today announced that it will hold a corporate update conference call for investors. The call will take place on Tuesday, July 26th at 4:30pm ET and will be hosted by the Company's Chief Executive Officer, Dr. Alan Tuchman, and its President and Chief Science Officer, Dr. Daniel Alkon. Drs. Tuchman and Alkon will also take live Q&A following their prepared remarks. The U.S. toll free dial-in for the conference call is (877) 407-8293, and the international dial-in number is 1-(201) 689-8349. Fo

      7/21/22 9:15:00 AM ET
      $SNPX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Synaptogenix Discloses Positive Results of Further Bryostatin Trial Analyses in Presentation at Alzheimer's Association International Conference 2021

      NEW YORK, July 26, 2021 /PRNewswire/ -- Synaptogenix, Inc. (NASDAQ:SNPX), an emerging biopharmaceutical company focused on developing therapies for neurodegenerative diseases, today announced that its abstract for presentation at the Alzheimer's Association International Conference (AAIC) is now available entitled "Bryostatin Restores Cognitive Functions Above Baseline in Advanced Alzheimer's Disease (AD) Patients: A Regenerative Therapeutic Strategy." "Recent further analyses of pre-specified cohort results revealed clear evidence of Bryostatin therapeutic efficacy for advanced AD patients.  Analyses of treatment benefit, based on mean differences and as a function of successive dosing in

      7/26/21 9:15:00 AM ET
      $SNPX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SNPX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Singer William S.

      4 - Synaptogenix, Inc. (0001571934) (Issuer)

      4/7/25 5:01:34 PM ET
      $SNPX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Schechter Jonathan

      4 - Synaptogenix, Inc. (0001571934) (Issuer)

      4/7/25 5:00:58 PM ET
      $SNPX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Bernstein Bruce

      4 - Synaptogenix, Inc. (0001571934) (Issuer)

      4/7/25 5:00:15 PM ET
      $SNPX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SNPX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Synaptogenix Appoints Crypto Expert to Lead Digital Asset Treasury Strategy Focused Exclusively on Top-Valued AI Token

      Singular focus on Bittensor (TAO), the leading AI token byadoption and market capitalization James Altucher to lead TAO token strategy initiatives Planned initial acquisition of $10 million in TAO equates to over two times the Company's current market capitalization; total acquisition target of $100 million NEW YORK, June 9, 2025 /PRNewswire/ -- Synaptogenix, Inc. (NASDAQ:SNPX) ("Synaptogenix" or the "Company") today announced its launch of a differentiated cryptocurrency treasury strategy focused exclusively on the artificial intelligence (AI) crypto token "TAO," which is currently the top AI token by market capitalization and adoption. Well-known cryptocurrency and AI expert James Altuch

      6/9/25 9:00:00 AM ET
      $SNPX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Synaptogenix Board of Directors Forms Special Committee to Explore Value Creation Opportunities Utilizing Balance Sheet Strength

      $19.6 million in cash and cash equivalents as of September 30, 2024 Dramatically reduced cash burn rate expected NEW YORK, Dec. 20, 2024 /PRNewswire/ -- Synaptogenix, Inc. (NASDAQ:SNPX) ("Synaptogenix" or the "Company"), an emerging biopharmaceutical company developing therapeutics for neurodegenerative disorders, today announced that its Board of Directors has formed an independent Special Committee to explore strategic opportunities to create and enhance value for investors. Funding for such opportunities is supported by the Company's robust financial position including $19.6 million in cash as of September 30, 2024, with approximately 1.3 million common shares outstanding. "Synaptogenix

      12/20/24 9:15:00 AM ET
      $SNPX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Synaptogenix Announces $5.0 Million Financing

      NEW YORK, Sept. 11, 2024 /PRNewswire/ -- Synaptogenix, Inc. (NASDAQ:SNPX) ("Synaptogenix" or the "Company"), an emerging biopharmaceutical company developing therapeutics for neurodegenerative disorders, today announced today announced that it has entered into securities purchase agreements for a $5.0 million financing with existing investors involving the sale of 5,000 shares of its newly issued Series C convertible preferred stock ("preferred stock"), with a stated value of $1,000 per share, convertible into shares of its common stock in a registered public offering (the "Registered Offering") and a concurrent private placement (the "Private Placement" and collectively with the Registered

      9/11/24 9:00:00 AM ET
      $SNPX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SNPX
    Leadership Updates

    Live Leadership Updates

    See more
    • Synaptogenix Appoints Crypto Expert to Lead Digital Asset Treasury Strategy Focused Exclusively on Top-Valued AI Token

      Singular focus on Bittensor (TAO), the leading AI token byadoption and market capitalization James Altucher to lead TAO token strategy initiatives Planned initial acquisition of $10 million in TAO equates to over two times the Company's current market capitalization; total acquisition target of $100 million NEW YORK, June 9, 2025 /PRNewswire/ -- Synaptogenix, Inc. (NASDAQ:SNPX) ("Synaptogenix" or the "Company") today announced its launch of a differentiated cryptocurrency treasury strategy focused exclusively on the artificial intelligence (AI) crypto token "TAO," which is currently the top AI token by market capitalization and adoption. Well-known cryptocurrency and AI expert James Altuch

      6/9/25 9:00:00 AM ET
      $SNPX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Synaptogenix Increases Stake in Innovative Psilocybin Drug Discovery Company through its Partnership with Cannasoul Analytics

      Supports IP development for novel mushroom genetics and therapeutics for multiple indications NEW YORK, April 9, 2024 /PRNewswire/ -- Synaptogenix, Inc. (NASDAQ:SNPX) ("Synaptogenix" or the "Company"), an emerging biopharmaceutical company developing therapeutics for neurodegenerative disorders, today announced that it has increased its stake in psilocybin drug discovery company PsygaBio through its previously announced partnership with Cannasoul Analytics ("Cannasoul"). Synaptogenix acquired a 25% stake in Cannasoul during November of 2023 in support of research and development for psilocybin mushroom and cannabinoid-based therapeutics. Cannasoul is founded by the Technion Research & Develo

      4/9/24 9:15:00 AM ET
      $SNPX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Synaptogenix President Daniel L. Alkon, M.D. Honored for Scientific Presentation at USC-Sponsored Forum on Age-Related Diseases and Neurodegenerative Disorders

      Bryostatin-1 benefits in severe Alzheimer's disease patients were statistically significant with respect to placebo at p < 0.007 NEW YORK, Dec. 19, 2023 /PRNewswire/ -- Synaptogenix, Inc. (NASDAQ:SNPX) ("Synaptogenix" or the "Company"), an emerging biopharmaceutical company developing therapeutics for neurodegenerative disorders, today announced that its President and Chief Scientific Officer, Daniel L. Alkon, M.D., was honored by the International Association of Biomedical Sciences for his presentation at the University of Southern California-sponsored IABS Forum-2023, a gathering of world-renowned neuroscientists and academics discussing "New Concepts for the Treatment of Neurodegenerative

      12/19/23 9:00:00 AM ET
      $SNPX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SNPX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Synaptogenix Inc. (Amendment)

      SC 13G/A - Synaptogenix, Inc. (0001571934) (Subject)

      2/6/24 10:16:19 AM ET
      $SNPX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Synaptogenix Inc. (Amendment)

      SC 13G/A - Synaptogenix, Inc. (0001571934) (Subject)

      2/8/23 6:05:21 AM ET
      $SNPX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Synaptogenix Inc. (Amendment)

      SC 13G/A - Synaptogenix, Inc. (0001571934) (Subject)

      1/18/23 4:28:57 PM ET
      $SNPX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SNPX
    SEC Filings

    See more
    • Synaptogenix Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Synaptogenix, Inc. (0001571934) (Filer)

      6/9/25 9:01:27 AM ET
      $SNPX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Synaptogenix Inc.

      10-Q - Synaptogenix, Inc. (0001571934) (Filer)

      5/15/25 4:15:59 PM ET
      $SNPX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-K filed by Synaptogenix Inc.

      10-K - Synaptogenix, Inc. (0001571934) (Filer)

      3/27/25 5:23:10 PM ET
      $SNPX
      Biotechnology: Pharmaceutical Preparations
      Health Care